Compositions and methods for modulating apolipoprotein C-III expression
First Claim
1. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 20 contiguous nucleobases complementary to an equal length portion of nucleobases 3533 to 3552 of SEQ ID NO:
- 3, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO;
3; and
wherein the conjugate group comprises;
1 Assignment
0 Petitions
Accused Products
Abstract
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
149 Citations
26 Claims
-
1. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 20 contiguous nucleobases complementary to an equal length portion of nucleobases 3533 to 3552 of SEQ ID NO:
- 3, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO;
3; and
wherein the conjugate group comprises;
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
- 3, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO;
Specification